UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of November, 2019
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date: 26 November 2019
 
Name of applicant:
 
GlaxoSmithKline plc
 
Name of scheme:
 
GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan
 
Period of return:
 
From:
 
1 May 2019
 
To:
 
31 October 2019
 
Balance of unallotted securities under scheme(s) from previous return:
 
153,724
 
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
 
0
 
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
 
0
 
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:
 
153,724
 
 
 
 
 
 
 
Name of contact:
 
Victoria Whyte
 
Telephone number of contact:
 
020 8047 5000
 
 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date: 26 November 2019
 
Name of applicant:
 
GlaxoSmithKline plc
 
Name of scheme:
 
GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares
 
Period of return:
 
From:
 
1 May 2019
 
To:
 
31 October 2019
 
Balance of unallotted securities under scheme(s) from previous return:
 
1,265,008
 
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
 
0
 
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
 
429,913
 
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:
 
835,095
 
 
 
 
 
 
 
Name of contact:
 
Victoria Whyte
 
Telephone number of contact:
 
020 8047 5000
 
 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date: 26 November 2019
 
Name of applicant:
 
GlaxoSmithKline plc
 
Name of scheme:
 
GlaxoSmithKline 2009 Share Option Plan - ADS
 
Period of return:
 
From:
 
1 May 2019
 
To:
 
31 October 2019
 
Balance of unallotted securities under scheme(s) from previous return:
 
5,911,296
 
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
 
0
 
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
 
519,880
 
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:
 
5,391,416
 
 
 
 
 
 
 
Name of contact:
 
Victoria Whyte
 
Telephone number of contact:
 
020 8047 5000
 
 
 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date: 26 November 2019
 
Name of applicant:
 
GlaxoSmithKline plc
 
Name of scheme:
 
GlaxoSmithKline plc Share Save Plan 2012
 
Period of return:
 
From:
 
1 May 2019
 
To:
 
31 October 2019
 
Balance of unallotted securities under scheme(s) from previous return:
 
2,326,896
 
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
 
0
 
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
 
181,084
 
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:
 
2,145,812
 
 
 
 
 
 
 
Name of contact:
 
Victoria Whyte
 
Telephone number of contact:
 
020 8047 5000
 
 
 
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: November 26, 2019 
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc